FATE Stock Analysis: Buy, Sell, or Hold?
FATE - Fate Therapeutics, Inc.
$2.92
-0.10 (-3.31%)
▼
5d:
+56.15%
30d:
+13.62%
90d:
+135.48%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When FATE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: FATE is 12.3% above its trading range ($2.60). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: FATE is 12.3% above its trading range ($2.60). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: FATE is currently trading at $2.92, which is considered extended relative to its 30-day fair value range of $1.91 to $2.60.
Technical Outlook: Technically, FATE is in a strong uptrend. The price is approaching resistance at $2.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: FATE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.41 (+85.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FATE is in a strong uptrend. The price is approaching resistance at $2.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: FATE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.41 (+85.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.91 -
$2.60
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Price significantly overextended (+12.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 85.3% below Wall St target ($5.41)
Trading Range Analysis
30-Day Trading Range
$1.91 -
$2.60
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.82
Resistance Level
$2.88
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.95
Wall Street Target
$5.41
(+85.3%)
Revenue Growth (YoY)
-20.3%
Share & Embed Analysis
Last updated: July 02, 2026 10:32 PM ET
Data refreshes hourly during market hours. Next update: 11:32 PM
Data refreshes hourly during market hours. Next update: 11:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FATE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Bahram Valamehr
SELL
5190 shares
2026-01-09
Cindy Tahl
SELL
10589 shares
2026-01-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$291 | 63 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$46 | 61 BUY |
